We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization.
Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity.
Please visit our webpage to know more about our products and offerings
https://iktos.ai/products/
Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity.
Please visit our webpage to know more about our products and offerings
https://iktos.ai/products/
Location: France, Ile-de-France
Employees: 11-50
Total raised: $16.62M
Founded date: 2016
Investors 3
| Date | Name | Website |
| 12.03.2023 | M Ventures | m-ventures... |
| 13.03.2023 | Debiopharm | debiopharm... |
| - | Agoranov | agoranov.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.03.2023 | Series A | $16.62M | - |
Mentions in press and media 15
| Date | Title | Description |
| 08.07.2024 | Iktos Corporation Iktos acquires Synsight, a life science technology company specializing in drug discovery targeting protein-protein and RNA-protein interactions. | [Ictos Co., Ltd.] Iktos acquires Synsight, a life sciences technology company specializing in drug discovery targeting protein-protein and RNA-protein interactions *Ictos Co., Ltd.* Press release: July 8, 2024 ** Iktos acquires Synsight, a ... |
| 14.02.2024 | Iktos Co., Ltd. France’s Iktos announces establishment of Japanese subsidiary “Iktos Co., Ltd.” | [Iktos Co., Ltd.] France’s Iktos announces establishment of Japanese subsidiary “Iktos Co., Ltd.” *View in browser* *Ictos Co., Ltd.* Press release: February 14, 2024 ** France’s Iktos announces establishment of Japanese subsidiary “Iktos C... |
| 04.07.2023 | Kissei introduces Iktos AI Drug Discovery System | Iktos, a company specialized in Artificial Intelligence for new drug design, announced that Kissei Pharmaceutical Co., Ltd. (“Kissei”), a Japanese pharmaceutical company with approximately 75 years of history, specialized in the field of ur... |
| 08.06.2023 | Iktos and Curreio Announce Collaboration Agreement in New Drug Discovery | Iktos, a company specialized in Artificial Intelligence for new drug design and Curreio, a Japanese company specializing in structural analysis of biomolecules using cryo-electron microscopy, announced a collaboration agreement in AI for ne... |
| 10.04.2023 | Il mercato del Venture Capital a marzo 2023 | Come è andato il mercato del Venture Capital a marzo 2023? Come sempre partiamo dai dati per poi passare ad alcune tra le startup, le scaleup e i round più interessanti. Il mese di marzo vede una leggera flessione della raccolta in Europa,... |
| 10.03.2023 | Iktos Raises € 15.5 Million Series a Round to Expand Its Artificial Intelligence-Based Drug Discovery Technologies and Solutions | Iktos, a company specializing in artificial intelligence for new drug discovery, announces the closing of a € 15.5 Million Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Ca... |
| 10.03.2023 | France-based Iktos raises EUR 15.5 million in Series A | Paris, France-based company specializing in artificial intelligence for new drug discovery, Iktos, raised EUR 15.5 million in Series A funding. The Series A round took place on March 9, 2023. New investors such as M Ventures and Debiopharm ... |
| 09.03.2023 | Iktos Raises €15.5M in Series A Funding | Iktos, a Paris, France-based company specializing in artificial intelligence for new drug discovery, raised €15.5M in Series A funding. The round was led by M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. Th... |
| 09.03.2023 | Iktos raises €15.5 million Series A round for AI drug discovery service | French start-up Iktos has raised a €15.5 million Series A round fuelling its launch of its drug discovery platform. Fresh to the Iktos cap table the round is co-led by M Ventures and Debiopharm Innovation Fund, and includes Omnes Capital. I... |
| 09.03.2023 | France-based Iktos raises €15.5M to expand its AI-based drug discovery technology | Paris-based Iktos, a company that specialises in artificial intelligence for new drug discovery, announced on Thursday that it has raised €15.5M in a Series A round of funding. The round was co-led by new investors M Ventures and Debiopharm... |
Show more